EnVVeno Medical (NVNO) climbed 3.6% in recent Tuesday trading after the medical technology company said it had filed a premarket approval application with the US Food and Drug Administration for its VenoValve implants to treat severe chronic venous insufficiency.
The completed application is supported by clinical data from a pivotal trial and includes proposed labeling for the device, the company said.
Chief Executive Officer Robert Berman said he anticipates a decision from the FDA in H2 of 2025. The regulator previously designated VenoValve as a breakthrough device, helping expedite the agency's evaluations.
Price: 3.43, Change: +0.12, Percent Change: +3.60
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.